Skip to main content
SpringerLink
Log in

Hepatitis

Treatment failure in chronic hepatitis B

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

The failure of antiviral therapy for chronic hepatitis B can involve both virological breakthrough and genotypic resistance. A study of the failure of nucleoside analogue therapy suggests that drug-resistant mutants are not solely responsible for treatment failure. Suboptimal treatment adherence might also have an important role.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Soriano, V., Perelson, A. S. & Zoulim, F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J. Antimicrob. Chemother. 62, 1–4 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Werle-Lapostolle, B. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750–1758 (2004).

    Article  CAS  PubMed  Google Scholar 

  3. Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593–1608 (2009).

    Article  CAS  PubMed  Google Scholar 

  4. Hongthanakorn, C. et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogs in clinical practice. Hepatology doi:10.1002/hep.2 4318.

  5. Snow-Lampart, A. et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53, 763–773 (2011).

    Article  CAS  PubMed  Google Scholar 

  6. Chang, T. T. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51, 422–430 (2010).

    Article  CAS  PubMed  Google Scholar 

  7. Osterberg, L. & Blaschke, T. Adherence to medication. N. Engl. J. Med. 353, 487–497 (2005).

    Article  CAS  PubMed  Google Scholar 

  8. Chotiyaputta, W., Peterson, C., Ditah, F. A., Goodwin, D. & Lok, A. S. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis. B. J. Hepatol. 54, 12–18 (2011).

    Article  CAS  PubMed  Google Scholar 

  9. Patterson, S. J. et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis. B. Gut 60, 247–254 (2011).

    Article  CAS  PubMed  Google Scholar 

  10. Lee, P. K., Kieffer, T. L., Siliciano, R. F. & Nettles, R. E. HIV-1 viral load blips are of limited clinical significance. J. Antimicrob. Chemother. 57, 803–805 (2006).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM, U1052, Cancer Research Center of Lyon, 151 cours Albert Thomas, 69003, Lyon, France

    Fabien Zoulim

Authors
  1. Fabien Zoulim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabien Zoulim.

Ethics declarations

Competing interests

F. Zoulim has been a Consultant for Bristol–Myers Squibb, Gilead and Novartis. He has also been on the Speakers' Bureau for Bristol–Myers Squibb and Gilead and has received grant/research support from Gilead and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zoulim, F. Treatment failure in chronic hepatitis B. Nat Rev Gastroenterol Hepatol 8, 366–367 (2011). https://doi.org/10.1038/nrgastro.2011.104

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2011.104

  • Springer Nature Limited

This article is cited by

Search

Navigation